You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Development of a novel bioabsorbable clip and applier for rapid closure of the dura mater in open and minimally invasive spine surgery.SBC: NeuraMedica Inc. Topic: NINDS
PROJECT SUMMARY ABSTRACT This Small Business Innovation Research Phase II project supports the development of a novel bioabsorbable surgical clip and applier for rapid closure of the dura mater in open and minimally invasive spine surgeryThe dura mater is the protective membrane that covers the brain and spinal cord and contains cerebrospinal fluidCSFOpenings in the duradurotomycan result in CSF l ...SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: NODDLE LLC Topic: SB152004
Graph analytics platforms are widely deployed across diverse domains to analyze large, unstructured and semi-structured data-sets. The ability to process large data-sets quickly is especially important in the domain of cyber security where detecting sophisticated attacks in a timely manner is crucially important for maintaining network security.While existing tools are clearly effective, there is ...SBIR Phase II 2016 Department of DefenseDefense Advanced Research Projects Agency
SBC: THERAPYX, INC. Topic: NIAID
DESCRIPTION provided by applicant Genital tract infection with Neisseria gonorrhoeae gonorrhea does not induce a state of specific protective immunity and can be acquired repeatedly Despite public health measures the disease persists at an unacceptably high frequency there is no vaccine against it and resistance even to the latest generations of antibiotics continues to emerge Recent fin ...SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
SBC: APTITUDE MEDICAL SYSTEMS INC Topic: 300
DESCRIPTION provided by applicant Nucleic acid aptamers have shown great promise as the synthetic alternative to monoclonal antibodies in therapeutics diagnostics and Randamp D tools Key advantages of aptamers comparing to antibodies include applicability to non immunogenic targets chemical and thermal stability low production cost and no batch to batch variation Nevertheless the potent ...SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: Assurance Technology Corporation Topic: AF171067
The space environment has a significant and deleterious effect on US space assets. Spacecraft anomalies that lead to effects ranging from data dropouts, decrease in capability, mission degradation and mission failure have occurred over the years. We propose to develop a Compact Energetic Charged Particle sensor (C-ECP), compatible with the limited resources of 100-kg class satellites, that will pr ...SBIR Phase II 2018 Department of DefenseAir Force
SBC: STAR LAB CORP. Topic: SB172007
Developing secure software is notoriously difficult, partially evidenced by the increasing trend in vulnerabilities disclosed per year. While significant effort has gone into developing tools and automated test frameworks, human behavioral aspects of the software development process have remained relatively unexplored. These behavioral aspects, such as relying on inexperienced developers or prolon ...SBIR Phase II 2019 Department of DefenseDefense Advanced Research Projects Agency
SBIR TOPIC 354: A NOVEL PREDICTIVE TEST FOR RESPONSE TO COMBINATION IMMUNOTHERAPIES FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)SBC: Biomarker Strategies, LLC Topic: NCI
In the proposed Phase II studywe will further develop our PathMAPImmunotherapy test to address an unmet clinical need within the NSCLC patient populationWe hope to create a test that is able to accurately predict clinical response to PDPD Ltargeted immune checkpoint inhibitors alone and in combination with chemotherapiesOur development work in Phase II will be based on our initial work performed i ...SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
A universal, scale-independent artificial intelligence-based platform for manufacturing high titer bacteriophage preparations for clinical applicationsSBC: INTRALYTIX INC Topic: 95
A universal, scale-independent artificial intelligence-based platform for manufacturing high titer bacteriophage preparations for clinical applications.SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
Expression of Phytocannabinoids in Yeast: a High Yield Platform for Low Abundance Natural Products (Phase II)SBC: LIBREDE Topic: R
AbstractCannabinoids are a class of natural products shown to treat a wide range of diseasesincluding epilepsyone of the most common neurological disordersEpilepsy affects people of all ageswith overmillion epileptics worldwide and overnew cases of epilepsy each year in the United States aloneEven with numerous anti epileptic drugsAEDavailableof patients have uncontrollable seizures that do not re ...SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: RIVANNA MEDICAL, INC. Topic: 300
PROJECT SUMMARY ABSTRACTThoracic epidural analgesiaTEAis the gold standard for treating acute pain following major thoracic and abdominal surgeries and in patients with fractured ribsOf themillion inpatient surgeries performed in the US each yearan estimatedmillion are eligible for TEAMultiple randomized control trials have demonstrated significantly improved patient outcomes when receiving TEA in ...SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health